Infant Bacterial Therapeutics AB (publ)

OM:IBT B Stok Raporu

Piyasa değeri: SEK 495.7m

Infant Bacterial Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Infant Bacterial Therapeutics CEO'su Staffan Stromberg, Jan2013 tarihinde atandı, in görev süresi 11.83 yıldır. in toplam yıllık tazminatı SEK 5.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 57.9% maaş ve 42.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.79% ine doğrudan sahiptir ve bu hisseler SEK 3.93M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 7.5 yıldır.

Anahtar bilgiler

Staffan Stromberg

İcra Kurulu Başkanı

SEK 5.3m

Toplam tazminat

CEO maaş yüzdesi57.9%
CEO görev süresi11.8yrs
CEO sahipliği0.8%
Yönetim ortalama görev süresi1.5yrs
Yönetim Kurulu ortalama görev süresi7.5yrs

Son yönetim güncellemeleri

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

CEO Tazminat Analizi

Staffan Stromberg'un ücretlendirmesi Infant Bacterial Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Sep 30 2018n/an/a

-SEK 26m

Jun 30 2018n/an/a

-SEK 22m

Mar 31 2018n/an/a

-SEK 37m

Dec 31 2017SEK 3mSEK 1m

-SEK 36m

Tazminat ve Piyasa: Staffan 'nin toplam tazminatı ($USD 492.93K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 239.32K ).

Tazminat ve Kazançlar: Staffan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Staffan Stromberg (57 yo)

11.8yrs

Görev süresi

SEK 5,327,000

Tazminat

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Staffan Stromberg
Chief Executive Officer11.8yrsSEK 5.33m0.79%
SEK 3.9m
Maria Ekdahl
Chief Financial Officer2.2yrsVeri yok0.031%
SEK 154.8k
Anders Kronström
Chief Operating Officer6.8yrsSEK 500.00k0.083%
SEK 411.9k
Thomas Schnitzer
Chief Scientific Officerless than a yearVeri yokVeri yok
Sanjiv Sharma
Head of Medical Affairsless than a yearVeri yokVeri yok
Jonas Rastad
Chief Medical Officerless than a yearVeri yokVeri yok

1.5yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: IBT B 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Peter Rothschild
Chairman13.8yrsSEK 727.00kVeri yok
Margareta Hagman
Independent Director9.2yrsSEK 153.00k0.039%
SEK 194.4k
Eva Idén
Independent Director7.5yrsSEK 153.00k0.0042%
SEK 20.6k
Kristina Nygren
Independent Director6.5yrsSEK 153.00k0.00074%
SEK 3.7k
Anthon Jahreskog
Independent Director7.5yrsSEK 193.00k0.18%
SEK 893.1k

7.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IBT B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).